Search

Your search keyword '"Gatell, Jose Maria"' showing total 10 results
Start Over Author "Gatell, Jose Maria" Publication Year Range Last 10 years
10 results on '"Gatell, Jose Maria"'

1. Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018)

Author

Pérez-Molina, José A., Polo, Rosa, López-Aldeguer, José, Lozano, Fernando, Aguirrebengoa, Koldo, Arribas, José Ramón, Boix, Vicente, Berenguer, Juan, Blanco, José Ramón, Domingo, Pere, Estrada, Vicente, Galindo, María José, García, Federico, Gatell, José María, González-García, Juan, Gutiérrez, Félix, Iribarren, José Antonio, Knobel, Hernando, Llibre, Josep María, López-Bernaldo de Quirós, Juan Carlos, López-Cortés, Luis Fernando, Losa, Juan Emilio, Mariño, Ana, Miró, José M., Montes, María L., Moreno, Santiago, Negredo, Eugenia, Pérez-Elías, María J., Podzamczer, Daniel, Portilla, Joaquín, Poveda, Eva, Pulido, Federico, Ribera, Esteban, Rivero, Antonio, Rubio, Rafael, Santos, Jesús, Sanz-Moreno, José, Sanz-Sanz, Jesús, Serrano, Sergio, de la Torre, Javier, Tuset, Montserrat, von Wichman, Miguel A., and Martínez, Esteban

Published
2019
Full Text
View/download PDF

6. Changes in Cognitive Function Over 96 Weeks in Naive Patients Randomized to Darunavir–Ritonavir Plus Either Raltegravir or Tenofovir–Emtricitabine: A Substudy of the NEAT001/ANRS143 Trial

Author

Winston, Alan, Stöhr, Wolfgang, Antinori, Andrea, Amieva, Helene, Perré, Philippe, De Wit, Stephane, Reynes, Jacques, Gompels, Mark, dʼArminio Monforte, Antonella, Gatell, Jose-Maria, Grarup, Jesper, Pozniak, Anton, Babiker, Abdel, Raffi, François, and Richert, Laura

Published
2017
Full Text
View/download PDF

8. Network meta-analysis of post-exposure prophylaxis randomized clinical trials

Author

Fernandez, I, deLazzari, E, Inciarte, A, Diaz-Brito, V, Milinkovic, A, Arenas-Pinto, A, Etcheverrry, F, Garcia, F, Leal, L, Domingo P., and Gatell, Jose Maria

Subjects
integrase inhibitors, exposure prophylaxis, education, cardiovascular system, HIV, post&#8208, completion, circulatory and respiratory physiology
Abstract

Objectives We performed a network meta-analysis of PEP randomized clinical trials to evaluate the best regimen. Methods After MEDLINE/Pubmed search, studies were included if: (1) were randomized, (2) comparing at least 2 PEP three-drug regimens and, (3) reported completion rates or discontinuation at 28 days. Five studies with 1105 PEP initiations were included and compared ritonavir-boosted lopinavir (LPV/r) vs. atazanavir (ATV) (one study), cobicistat-boosted elvitegravir (EVG/c) (one study), raltegravir (RAL) (one study) or maraviroc (MVC) (two studies). We estimated the probability of each treatment of being the best based on the evaluation of five outcomes: PEP non-completion at day 28, PEP discontinuation due to adverse events, PEP switching due to any cause, lost to follow-up and adverse events. Results Participants were mostly men who have sex with men (n = 832, 75%) with non-occupational exposure to HIV (89.86%). Four-hundred fifty-four (41%) participants failed to complete their PEP course for any reason. The Odds Ratio (OR) for PEP non-completion at day 28 in each antiretroviral compared to LPV/r was: ATV 0.95 (95% CI 0.58-1.56; EVG/c: OR 0.65 95% CI 0.30-1.37; RAL: OR 0.68 95% CI 0.41-1.13; and MVC: OR 0.69 95% CI 0.47-1.01. In addition, the rankogram showed that EVG/c had the highest probability of being the best treatment for the lowest rates in PEP non-completion at day 28, switching, lost to follow-up or adverse events and MVC for PEP discontinuations due to adverse events. Conclusions Our study shows the advantages of integrase inhibitors when used as PEP, particularly EVG as a Single-Tablet Regimen.

Published
2021

9. Rate and predictors of progression in elite and viremic HIV-1 controllers.

Author

Leona, Agathe, Perez, Ignacio, Ruiz-Mateos, Ezequiel, Benito, Jose Miguel, Leal, Manuel, Lopez-Galindez, Cecilio, Rallon, Norma, Alcami, Jose, Lopez-Aldeguer, Jose, Viciana, Pompeyo, Rodriguez, Carmen, Grau, Eulalia, Iribarren, Jose, Gatell, Jose Maria, Garcia, Felipe, Leon, Agathe, and EC and Immune Pathogenesis Working group of the Spanish AIDS Research Network

Published
2016
Full Text
View/download PDF

10. Changes in Cognitive Function Over 96 Weeks in Naive Patients Randomized to Darunavir-Ritonavir Plus Either Raltegravir or Tenofovir-Emtricitabine: A Substudy of the NEAT001/ANRS143 Trial.

Author

Winston A, Stöhr W, Antinori A, Amieva H, Perré P, De Wit S, Reynes J, Gompels M, dʼArminio Monforte A, Gatell JM, Grarup J, Pozniak A, Babiker A, Raffi F, and Richert L

Subjects
Adult, Female, Humans, Male, Middle Aged, Neuropsychological Tests, Treatment Outcome, AIDS Dementia Complex drug therapy, AIDS Dementia Complex pathology, Anti-Retroviral Agents administration & dosage, Antiretroviral Therapy, Highly Active methods, Cognition physiology, HIV Infections complications, HIV Infections drug therapy
Abstract

Background: Improvements in cognitive function are described after initiation of combination antiretroviral therapy (cART), with sparse data on differences between cART strategies., Methods: We assessed changes in cognition, over 96 weeks, in therapy-naive HIV-positive adults randomized to darunavir/ritonavir (800/100 mg once daily) with either raltegravir (400 mg twice daily, Arm1) or tenofovir/emtricitabine (245/200 mg once daily, Arm2). Seven cognitive tests were administered at baseline and week (W) 96. Changes from baseline in individual cognitive test scores and composite score (NPZ) were assessed. Comparisons between treatment arms were by intention to treat and associations with immunological and virological parameters by regression models., Findings: Of 343 subjects enrolled, 208 completed the W96 cognitive assessment. Baseline median (interquartile range) CD4 count and plasma HIV RNA were 348 (282-398) cells per microliter and 4.7 (4.2-5.1) log10 copies per milliliter, respectively. At W96, numbers with plasma HIV RNA undetectable and remaining on randomized cART were 85 (92%) and 110 (96%), and 84 (90%) and 107 (93%) in Arm1 and Arm2, respectively. Overall performance significantly improved by W96 in 5 of 7 individual tests and in NPZ. Mean changes in NPZ were 0.28 versus 0.21 for Arm1 and 2, respectively (P = 0.37). No statistically significant differences between study treatment arms were observed in individual cognitive domains apart from attention (greater improvement in Arm1, P = 0.0499). At W96, NPZ score increase was associated with increase in CD4 (P = 0.001) but not HIV RNA area under curve (P = 0.60)., Interpretation: Subsequent to the initiation of cART, immunological recovery rather than type of antiretroviral therapy is the major driver of changes in cognitive function.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results